Study #2009-1002
A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
Description
This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study phase:
I/II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.